Sep. 13 at 4:59 PM
$ABCL PART 1 of 1
Lets try to put a number on ABCL635.
$ABCL’s VALUATION?
At
$10.89, AbCellera is worth approximately
$3.3B.
The company reported
$540M in cash and marketable securities before raising roughly
$187M net from its recent offering.
Very roughly, investors are paying
$2.6B above cash for ABCL635, the remaining pipeline, partnered programs and the entire platform.
Now let’s model the drug.
Veozah and Lynkuet have annual US list prices of approximately
$6,600 and
$7,500.
To stay conservative, I’ll assume ABCL635 generates only
$5,000 in annual net revenue per patient after discounts and rebates.
That would produce:
• 100,000 patients =
$500M annually
• 250,000 patients =
$1.25B annually
• 500,000 patients =
$2.5B annually
At 250,000 patients, ABCL635 becomes a blockbuster.
🚨At 500,000, one drug could completely transform AbCellera.
One analyst cited by Reuters estimates a
$6B market opportunity and approximately
$2.3B in potential peak sales for ABCL635.
